To examine whether the presence, or development, of atrial fibrillation in patients with advanced chronic heart failure, is associated with a poorer prognosis, compared to patients with sinus rhythm and chronic heart failure.
Introduction
Atrial fibrillation has become the most common cardiac arrhythmia, and is associated with significant morbidity and mortality during follow-up [1] [2] [3] [4] [5] [6] . Chronic heart failure is the most frequent precursor of atrial fibrillation, and the risk of developing atrial fibrillation during long-term follow-up appears to be 5-10 times higher in patients with chronic heart failure at baseline than in those without this syndrome [1, 2, 4, 7] . The incidence of both chronic heart failure and atrial fibrillation markedly increases in the elderly [4, [8] [9] [10] , and in the light of the ageing population, both diseases have been called the two new epidemics of cardiovascular disease [11] . Atrial fibrillation is common in patients with chronic heart failure, and increases with the severity of the disease. Atrial fibrillation has been reported to be present in up to 40% in patients with advanced chronic heart failure (New York Heart Association [NYHA]) class III-IV [5] . From an epidemiological point of view, atrial fibrillation in patients with chronic heart failure is therefore a clinically relevant problem, but in many large chronic heart failure trials, atrial fibrillation patients were either excluded from participation, or were not reported or analysed separately. The prognostic significance of atrial fibrillation in patients with chronic heart failure has not been fully elucidated [5, 6, 12, 13] . While Middlekauff et al. in an earlier study reported increased mortality in patients with advanced chronic heart failure and atrial fibrillation, as compared to those with sinus rhythm [5] , more recent data from this same group showed no significant difference in prognosis between patients with atrial fibrillation and sinus rhythm [12] . In patients with milder chronic heart failure, data are also conflicting since one study found no difference in mortality [6] , while a recent substudy from SOLVD showed that atrial fibrillation was associated with an increased risk for all-cause mortality [13] . While the prognostic significance of chronic atrial fibrillation in patients with chronic heart failure is therefore not clear, even fewer data are available regarding the development of atrial fibrillation in chronic heart failure patients. One recent study suggested that newly developed atrial fibrillation was associated with a poorer prognosis [14] . Furthermore, conversion to sinus rhythm of patients with previous atrial fibrillation (by amiodarone) was recently found to be associated with an improved prognosis [15] . The aim of the present study was to examine the prognostic significance of chronic atrial fibrillation in a large, and well-documented population of patients with moderate to severe chronic heart failure, and also to investigate the clinical implications of the development of atrial fibrillation during long-term follow-up.
Methods

Study design and patient population
All patients in the present study participated in a recent survival trial (PRIME-II: Prospective Randomized study of Ibopamine on Mortality and Efficacy) [16] . The present patient population consists of patients who were enrolled in the Netherlands. PRIME-II was designed to investigate the effect of the oral dopamine agonist ibopamine on all-cause mortality in patients with moderate to severe chronic heart failure. In short, patients aged 18-80 years were eligible for PRIME-II if they had signs and symptoms of moderate to severe chronic heart failure (NYHA functional class III-IV) despite optimal medical treatment. Drug treatment at baseline consisted of angiotensin converting enzyme (ACE) inhibitors (unless intolerant), diuretics (in a dose of furosemide d80 mg / day 1 [or equivalent] if ACE inhibitors were not prescribed, or d40 mg . day 1 , when combined with an ACE inhibitor), and, if deemed indicated, digoxin and vasodilators. Evidence of left ventricular dysfunction had to be proved by one or more of the following techniques: (a) left ventricular ejection fraction <0·35 (measured by radionuclide or contrast ventriculography, or by echocardiography), (b) a left ventricular internal end-diastolic diameter of >60 mm, or a fractional shortening of <20% on echocardiography, or (c) a cardiothoracic ratio on a chest X-ray of >0·50. Exclusion criteria included: obstructive valve disease, obstructive or restrictive cardiomyopathy, and potentially transient causes of chronic heart failure such as myocarditis, myocardial infarction or cardiac surgery within the previous 3 months, uncontrolled arrhythmias, other non-cardiac high-risk underlying medical conditions, and administration of investigational drugs within the last 30 days before randomization. In addition to the main PRIME-II protocol, the majority of the patients enrolled in The Netherlands (372 of the 427 patients) also participated in a pre-defined neurohormonal substudy [17, 18] . The following plasma neurohormones were measured: norepinephrine, epinephrine, dopamine, renin, aldosterone, atrial natriuretic peptide, N-terminal atrial natriuretic peptide, brain natriuretic peptide, and endothelin. All the measurements were performed at a core laboratory at the University Hospital Dijkzigt, Rotterdam, The Netherlands, and the methodology used has previously been described in detail [17] [18] [19] . In the present study, only patients with sinus rhythm or atrial fibrillation were enrolled. Chronic atrial fibrillation at baseline was defined using standard criteria [5] : irregular undulation of the baseline, generally associated with irregular ventricular rhythm, which had to be recorded on two consecutive ECGs, at least 7 days apart. Development of atrial fibrillation during the study was defined when atrial fibrillation was recorded on at least two occasions, at least 7 days apart. The study protocol was approved by the local Ethical Committee of each participating medical centre, and all patients gave their written informed consent before entry into the study.
Study enrolment and follow-up
Patient enrolment began in September 1992, but the PRIME-II Study was prematurely discontinued in August 1995 when a significantly higher fatality rate was observed in the ibopamine group than in the placebo group [16] . At that time, 427 patients had been enrolled in The Netherlands in 25 centres. During a follow-up of 5-982 days (mean 354), 25% of patients had died. Within 2 weeks, all patients who were still on study medication (ibopamine or placebo), discontinued this medication.
After discontinuation of PRIME-II, all patients were followed for at least 2 years until the present Prognosis of atrial fibrillation and heart failure 1239 assessment, which took place between September 1997 and September 1998. During this time, patients were treated by their own physicians, and continued standard medication for chronic heart failure. At follow-up, all patients who were alive at the end of PRIME-II were reassessed. One investigator (G.T.) visited all centres that had been involved in PRIME-II, and a questionnaire was completed that included current status, rhythm, and medication. Of the patients who died, both the time of death as well as mode of death were investigated. If the data were not complete, general practitioners were contacted for additional information.
Statistical analysis
Categorical baseline data were compared between patients with atrial fibrillation and patients with sinus rhythm by Fisher's Exact test, or the chi-square test (NYHA functional class). Continuous baseline data were compared by Student's t-test if normally distributed, and by Wilcoxon 2-sample if the distribution was skewed.
The study focused on the prognostic significance of the presence of atrial fibrillation at baseline, and the development of atrial fibrillation in the course of the study. Two Kaplan-Meier survival curves were therefore constructed:
(1) comparing survival of patients with either atrial fibrillation or sinus rhythm at baseline, and (2) comparing survival of patients developing atrial fibrillation in the course of the study, with survival of those who remained in sinus rhythm throughout the study. Furthermore, the cumulative incidence of the development of atrial fibrillation during follow-up, of the subgroup of patients with sinus rhythm at baseline, was estimated using the Kaplan-Meier method.
The effect on survival of the presence of atrial fibrillation at baseline, and the effect of the development of atrial fibrillation during the study, were investigated using the Cox-proportional hazards model [20] . In a univariate Cox regression analysis, the effect of baseline characteristics on survival was tested. To examine linearity with respect to survival, continuous variables were divided in quartiles. If the risk-ratio for quartiles 2, 3 and 4 showed a gradual increase, or decrease, the variable was taken as continuous in the model. If the risk increased or decreased more than proportionally, quartiles with comparable risk ratios were combined and the variable was included in the model as a dichotomous variable.
Using backward selection, a multiple Cox regression model was constructed, in which the effect of atrial fibrillation was corrected for all significant confounding variables. Clinical characteristics with a univariate P-value <0·10 were selected for the multiple Cox regression analysis (Table 2) . Concomitant medication was not included in the multivariate analysis. The same procedure was followed to derive a multiple Cox regression model with significant predictors of the cumulative incidence of atrial fibrillation during followup. A two-sided, 95% confidence interval was constructed around each point estimate of risk ratio, and a P-value <0·05 was considered statistically significant. All statistical analyses were carried out using the Statistical Analysis System program (SAS), version 6.12 (Cary, NC).
Results
Patient population
Of the 427 patients who were enrolled in The Netherlands, 409 patients had either sinus rhythm (n=325) or atrial fibrillation (n=84); the remaining 18 patients had pacemaker rhythms and were excluded from the present analysis. During the PRIME-II study period, 49% of patients in sinus rhythm and 55% of patients in atrial fibrillation were randomized to ibopamine (P=0·33). The baseline demographics of the 409 study patients are presented in Table 1 . In general, atrial fibrillation patients were older (70 vs 67 years) and had longer lasting and slightly more advanced chronic heart failure, as judged by a higher cardiothoracic ratio on the chest X-ray, lower blood pressure and higher blood urea. Drug use was also not similar for the various classes of drugs, and more digoxin, antiarrhythmic drugs (90% amiodarone), and anticoagulants were used in patients with atrial fibrillation. Plasma neurohormones were generally higher in patients with atrial fibrillation. In particular N-terminal atrial natriuretic peptide, atrial natriuretic peptide, endothelin, and renin were higher while the difference was not statistically significant for the other neurohormones.
Survival analysis
Follow-up was 100% complete, and all 409 patients could be analysed. During a follow-up of 3·4 years (range 2·0-5·4 years), 203 of the 409 patients died (50%). In general, patients who died were older, and had more advanced chronic heart failure ( Table 2) . The majority of patients died of progressive chronic heart failure/cardiogenic shock (55%), or died suddenly (28%); 10% died of myocardial infarction or cerebrovascular accident and 4% died of cancer. Of the patients with atrial fibrillation, 50 of the 84 died (60%), as compared to 153 of the 325 patients with sinus rhythm (47%) (P=0·04 between groups, risk ratio 1·40, 95% CI 1·01-1·92) (Fig. 1) . Other factors that were also related to mortality on univariate analysis included: left ventricular ejection fraction, NYHA class, cardiothoracic ratio (chest X-ray), age, renal function, diabetes, systolic and diastolic blood pressure, serum sodium, and medication (digoxin and nitrates) all P<0·05 ( Table 2 ). Randomization to ibopamine during the PRIME-II study period was not related to mortality (P=0·49).
In the multivariate model, a number of these factors remained significantly related to a poorer prognosis (Table 3 ). In addition to parameters that directly reflect severity of chronic heart failure, such as low left ventricular ejection fraction, higher NYHA class and higher cardiothoracic ratio, older age, serum urea, and low diastolic blood pressure also remained significantly related to prognosis. In contrast, the presence of atrial fibrillation at baseline was not independently associated with an adverse prognosis.
Development of atrial fibrillation during the study
Of the 325 patients who had sinus rhythm at baseline, 30 patients (9%) developed atrial fibrillation in the course of the study, leading to a cumulative incidence of 15% at the end of the study (Fig. 2) . At baseline, patients who developed atrial fibrillation in the course of the study were older (mean age 70 years for those who developed atrial fibrillation, vs 66 years for those who remained in sinus rhythm throughout the study, P<0·007), had a lower systolic blood pressure (mean 120 mmHg vs 127 mmHg, respectively, P=0·049), and 
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had lower plasma norepinephrine concentrations (median 403 pg . ml 1 vs 488 pg . ml 1 , respectively, P=0·038), but the two groups were otherwise remarkably similar. Randomization to ibopamine during the PRIME-II study period was not associated with the development of atrial fibrillation (P=1·0).
During follow-up, 14 of the 30 patients (47%) who had developed atrial fibrillation in the course of the study died, compared to 139 of the 295 patients (47%) who remained in sinus rhythm throughout the study (Fig. 3) (P=ns between groups) . Multivariate analysis showed that both age and systolic blood pressure remained significantly related to new onset of atrial fibrillation.
Discussion
Atrial fibrillation is common in patients with advanced chronic heart failure, but data regarding its clinical and prognostic significance are scarce and inconclusive.
Although there are many theoretical considerations as to why the presence and development of atrial fibrillation in patients with advanced chronic heart failure could be expected to be associated with an adverse prognosis, the present study does not support this notion. Although mortality was overall higher in patients with atrial fibrillation at baseline, than in those with sinus rhythm, atrial fibrillation was not independently related to increased mortality. This finding suggests that factors associated with chronic heart failure, or caused by atrial fibrillation, may play a role. Development of atrial fibrillation in patients with sinus rhythm was also not a sign of clinical deterioration, as it was not associated with a worse outcome. However, given the relatively low number of these patients, and the sometimes rather short time after development of atrial fibrillation, such an association cannot be excluded.
In trying to establish whether atrial fibrillation per se is related to a poor outcome in patients with chronic heart failure, one would have to be certain that true comparisons or identical matches can be made with patients in sinus rhythm. This, however, may well prove impossible, since atrial fibrillation itself may lead to pathological and haemodynamic changes. These changes are caused by the loss of atrial contraction, irregular ventricular filling, and inappropriately high heart rates (particularly during exercise), and the latter may lead to the development of tachycardiomyopathy [9] . As a result, left ventricular ejection fraction, exercise capacity, and peripheral flow decrease [21, 22] , leading to an increase in signs and symptoms, and a worse NYHA functional class. This decrease in peripheral perfusion in patients with atrial fibrillation may also be associated with the observed increases in vasoconstrictive plasma neurohormones, in particular endothelin [18] . Also, atrial fibrillation may lead to a decrease in blood pressure and an impairment of renal perfusion and function. Further, the presence of atrial fibrillation may lead to the prescription of drugs which may not necessarily have a favourable effect on survival in chronic heart failure [23] . In a multivariate model, one can adjust the risk of atrial fibrillation by eliminating all these factors, thereby possibly underestimating the true effect of atrial fibrillation.
A number of studies have examined the effect of atrial fibrillation on prognosis in patients with chronic heart failure, which have been discussed before by Carson et al. [6] . Most of these studies were small, or had a relatively short follow-up. Of the four larger studies [6, 12, 13, 24] , the three in patients with moderate to severe chronic heart failure showed that presence of atrial fibrillation had no effect on mortality [6, 12] . One study, however, which analysed data from patients with mild chronic heart failure (>80% NYHA class I-II) who participated in SOLVD, showed that after multivariate analysis, presence of atrial fibrillation remained significantly related to a poorer outcome, with a risk ratio of 1·34 (95% CI 1·12-1·62) [13] . Interestingly, in subjects without left ventricular dysfunction or chronic heart failure, the presence of atrial fibrillation is also associated with at least 1·5-2·0-fold mortality risk on multivariate analysis [2, 25, 26] . Together, these data may therefore suggest that atrial fibrillation is associated with increased mortality only in patients with (relatively) preserved left ventricular function, while in patients with advanced chronic heart failure, the relationship becomes more complicated, and is disturbed by differences in other variables.
The onset or development of atrial fibrillation was strongly related to age in the present study, which is in line with previous observations [3, 4, 27] . However, new onset of atrial fibrillation was not associated with a poorer outcome, in contrast to the report by Pozzoli et al. [14] , who studied patients with milder chronic heart failure. In population studies in subjects with normal left ventricular function, the development of atrial fibrillation was associated with other cardiovascular risk factors [27] , and with an increased mortality risk of 1·5-1·9 [3] . After myocardial infarction, new onset atrial fibrillation was also shown to be associated with an increased 30-day, and 1-year mortality [4, 28] . It is therefore tempting to speculate that, similar to differences regarding the prognostic impact of presence of chronic atrial fibrillation, the prognostic value of development of atrial fibrillation may also depend on the severity of chronic heart failure. In other words, when atrial Prognosis of atrial fibrillation and heart failure 1243 fibrillation develops in patients with advanced chronic heart failure, it is possibly a rather late event, which bears no prognostic value. (Serial) electrical cardioversion to restore or maintain sinus rhythm was not attempted in the present study, since it has been shown that this is in general unsuccessful in this setting, and the relapse rate is high [29, 30] . The present data may be interpreted as supportive for this approach, since development of atrial fibrillation did not favourably affect prognosis. Indeed, rate control, both at rest and during exercise has emerged as possibly more important in these patients, and drugs such as amiodarone and betablockers [31] may be more effective in this respect. While amiodarone was indeed more often used in patients with atrial fibrillation in this study, the use of betablockers was low, and not different between groups. Both drugs may also be used to prevent the development of tachycardiomyopathy in atrial fibrillation, and the higher incidence (27 vs 14%) of 'idiopathic dilated cardiomyopathy' in patients with atrial fibrillation raises the question whether some of them may not have had a tachycardiomyopathy.
No studies are available which exactly match each atrial fibrillation patient with a sinus rhythm patient, and our study also suffers from this limitation. We tried to overcome this by very carefully characterizing the baseline populations, including complete neurohormonal profiles, which has not been done in other studies. This allows careful assessment of differences in the patient populations, which can be corrected for by multivariate analyses. Nevertheless, comparison between two such groups remains difficult, and the present data should thus be used to generate new hypotheses.
Conclusions
In patients with advanced chronic heart failure, the presence of atrial fibrillation or the development of atrial fibrillation is not independently associated with an adverse prognosis. However, given the observed increased overall mortality in patients with atrial fibrillation, it is tempting to speculate that this is related to factors secondary to atrial fibrillation, such as left ventricular deterioration and reduction in blood pressure, leading to impairment of peripheral perfusion. 
